Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Dicerna Pharmaceuticals logo — Pioneering breakthroughs in genetic disorders and liver dise...

Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Founded 2007 201-500 employees Post-IPO Equity Total: $420.45M Biotechnology, Health Care +1

General Information

Company Name Dicerna Pharmaceuticals
Founded Year 2007
Founders / Decision Makers
Team member Team member Team member
Employees 201-500
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Dicerna Pharmaceuticals. To contact Dicerna Pharmaceuticals, visit dicerna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Dicerna Pharmaceuticals compare?

A PDF of Dicerna Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Dicerna Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biotechnology firm pioneering breakthroughs in genetic disorders and liver diseases through RNA interference technology. The company, founded in 2007, is headquartered in Lexington, Massachusetts. Dicerna focuses on developing treatments for rare inherited liver diseases, cancers, and other liver-related conditions utilizing ribonucleic acid interference (RNAi) technology. Its product candidates include DCR-PHXC for primary hyperoxaluria, DCR-undisclosed for an orphan genetic disease, DCR-PCSK9 for cardiovascular disease, and DCR-HBV for hepatitis B virus. With the most recent $100.00MPost-IPO Equity investment on 29 October 2018, Dicerna Pharmaceuticals has garnered investment from Eli Lilly and Cowen Group. The company operates within the industries of Biotechnology, Health Care, and Pharmaceutical.

Business keywords: RNA Interference, Genetic Disorders, Liver Diseases, Rare Diseases, Therapeutics, RNAi Technology, Pharmaceuticals, Drug Discovery, Inherited Liver Diseases, Cancer Treatment, Cardiovascular Disease, Hepatitis B, Orphan Genetic Diseases, Medical Research

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $100.00M 2
Eli Lilly
Eli Lilly, Cowen Group
29 Oct 2018
Post IPO Equity $100.00M -
16 May 2018
Post IPO Debt $70.00M 6
RA Capital Management Skyline Ventures Domain Associates
RA Capital Management, Skyline Ventures +4
30 Mar 2017
Post IPO Equity $49.00M -
20 May 2015
Series C $60.00M 9
RA Capital Management Skyline Ventures Abingworth
RA Capital Management, Skyline Ventures +7
31 Jul 2013
Series B $4.00M 2
HealthCare Ventures SR One
HealthCare Ventures, SR One
21 Oct 2010
Series B $29.05M -
05 Aug 2010
Series A $8.40M 3
Skyline Ventures Abingworth Oxford Bioscience Partners
Skyline Ventures, Abingworth +1
15 Jul 2008

Dicerna Pharmaceuticals Alternatives & Competitors

View All Alternatives
Dicerna Pharmaceuticals vs
Genecure
Genecure

Innovative gene transfer technology aiming to combat genetic disorders, infectious diseases, and can...

Venture round
Biotechnology, Health Care
Dicerna Pharmaceuticals vs
Benitec Biopharma Inc.
Benitec Biopharma Inc. United States

Silencing genes for life

Post-IPO Equity
16 employees
Biotechnology, Health Care
Dicerna Pharmaceuticals vs
Dynacure
Dynacure France

Dynacure develops new treatments for orphan disorders, focusing on CNM through Dyn101 program with I...

Series C
Biotechnology, Health Care
Also compare with: Dicerna Pharmaceuticals vs HemoShear Therapeutics HemoShear Therapeutics View all alternatives

FAQ About Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.
Dicerna Pharmaceuticals was founded in 2007.
Dicerna Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on RNA Interference, Genetic Disorders, Liver Diseases and Rare Diseases.
Dicerna Pharmaceuticals has approximately 201-500 employees.
Dicerna Pharmaceuticals has completed 8 funding rounds, raising a total of $420.45M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Dicerna Pharmaceuticals include Genecure, Benitec Biopharma Inc., Dynacure, Acceleron Pharma, Versantis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dicerna Pharmaceuticals and Genecure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dicerna Pharmaceuticals, https://bouncewatch.com/company/dicerna-pharmaceuticals-1, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout